LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Gross Profit Margin (Quarterly) : 86.58% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 86.58% |
| June 30, 2026 | 94.90% |
| March 31, 2026 | 37.56% |
| Date | Value |
|---|---|
| December 31, 2025 | 66.94% |
| September 30, 2025 | 99.00% |
| June 30, 2025 | 99.62% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| EyePoint, Inc. | -70.37% |
| Ligand Pharmaceuticals, Inc. | 83.68% |
| Bristol Myers Squibb Co. | 64.79% |
| Context Therapeutics, Inc. | -- |
| Neumora Therapeutics, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -61.74% |
| Return on Assets | -56.77% |
| Return on Invested Capital | -61.55% |
| Profit Margin (Quarterly) | -915.2% |
| Operating Margin (Quarterly) | -972.8% |
| Return on Net Operating Assets | -2.30K% |